{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:59:07Z","timestamp":1792205947936,"version":"4.4.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1212\/con.0000000000000289","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T10:23:55Z","timestamp":1454667835000},"page":"132-156","source":"Crossref","is-referenced-by-count":31,"title":["Antiepileptic Drugs"],"prefix":"10.1212","volume":"22","author":[{"given":"Bassel W.","family":"Abou-Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","unstructured":"Vajda FJ Eadie MJ. The clinical pharmacology of traditional antiepileptic drugs. Epileptic Disord 2014; 16(4): 395\u2013408. doi:10.1684\/epd.2014.0704.","DOI":"10.1684\/epd.2014.0704"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","unstructured":"Ding D Zhang Q Zhou D et al. Cognitive and mood effects of phenobarbital treatment in people with epilepsy in rural China: a prospective study. J Neurol Neurosurg Psychiatry 2012; 83(12): 1139\u20131144. doi:10.1136\/jnnp-2012-303042.","DOI":"10.1136\/jnnp-2012-303042"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","unstructured":"Mattson RH Cramer JA Collins JF et al. Comparison of carbamazepine phenobarbital phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313(3): 145\u2013151. doi:10.1056\/NEJM198507183130303.","DOI":"10.1056\/NEJM198507183130303"},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","unstructured":"Rowan AJ Ramsay RE Collins JF et al. New onset geriatric epilepsy: a randomized study of gabapentin lamotrigine and carbamazepine. Neurology 2005; 64(11): 1868\u20131873. doi:10.1212\/01.WNL.0000167384.68207.3E.","DOI":"10.1212\/01.WNL.0000167384.68207.3E"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","unstructured":"Baulac M Brodie MJ Patten A et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3 randomised double-blind non-inferiority trial. Lancet Neurol 2012; 11(7): 579\u2013588. doi:10.1016\/S1474-4422(12)70105-9.","DOI":"10.1016\/S1474-4422(12)70105-9"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","unstructured":"Azar NJ Wright AT Wang L et al. Generalized tonic-clonic seizures after acute oxcarbazepine withdrawal. Neurology 2008; 70(22 pt 2): 2187\u20132188. doi:10.1212\/01.wnl.0000313152.89906.5a.","DOI":"10.1212\/01.wnl.0000313152.89906.5a"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","unstructured":"Nolan SJ Muller M Tudur Smith C Marson AG. Oxcarbazepine versus phenytoin monotherapy for epilepsy. Cochrane Database Syst Rev 2013; 5: CD003615. doi:10.1002\/14651858.CD003615.pub3.","DOI":"10.1002\/14651858.CD003615.pub3"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","unstructured":"Hebeisen S Pires N Loureiro AI et al. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine oxcarbazepine and lacosamide. Neuropharmacology 2015; 89: 122\u2013135. doi:10.1016\/j.neuropharm.2014.09.008.","DOI":"10.1016\/j.neuropharm.2014.09.008"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","unstructured":"Nunes T Rocha JF Falca\u02dco A et al. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia 2013; 54(1): 108\u2013116. doi:10.1111\/j.1528-1167.2012.03595.x.","DOI":"10.1111\/j.1528-1167.2012.03595.x"},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","unstructured":"Sperling MR Harvey J Grinnell T et al. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America. Epilepsia 2015; 56(4): 546\u2013555. doi:10.1111\/epi.12934.","DOI":"10.1111\/epi.12934"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","unstructured":"Vajda FJ O\u2019brien TJ Hitchcock A et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004; 11(8): 854\u2013858. doi:10.1016\/j.jocn.2004.05.003.","DOI":"10.1016\/j.jocn.2004.05.003"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","unstructured":"Christensen J Gr\u00f8nborg TK S\u00f8rensen MJ et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013; 309(16): 1696\u20131703. doi:10.1001\/jama.2013.2270.","DOI":"10.1001\/jama.2013.2270"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","unstructured":"Meador KJ Baker GA Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 2013; 12(3): 244\u2013252. doi:10.1016\/S1474-4422(12)70323-X.","DOI":"10.1016\/S1474-4422(12)70323-X"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","unstructured":"Marson AG Al-Kharusi AM Alwaidh M et al. The SANAD study of effectiveness of valproate lamotrigine or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369(9566): 1016\u20131026. doi:10.1016\/S0140-6736(07)60461-9.","DOI":"10.1016\/S0140-6736(07)60461-9"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","unstructured":"Glauser TA Cnaan A Shinnar S et al. Ethosuximide valproic acid and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia 2013; 54(1): 141\u2013155. doi:10.1111\/epi.12028.","DOI":"10.1111\/epi.12028"},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","unstructured":"Glauser TA Cnaan A Shinnar S et al. Ethosuximide valproic acid and lamotrigine in childhood absence epilepsy. N Engl J Med 2010; 362(9): 790\u2013799. doi:10.1056\/NEJMoa0902014.","DOI":"10.1056\/NEJMoa0902014"},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","unstructured":"Riss J Cloyd J Gates J Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008; 118(2): 69\u201386. doi:10.1111\/j.1600-0404.2008.01004.x.","DOI":"10.1111\/j.1600-0404.2008.01004.x"},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","unstructured":"Gidal BE DeCerce J Bockbrader HN et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res 1998; 31(2): 91\u201399. doi:10.1016\/S0920-1211(98)00020-5.","DOI":"10.1016\/S0920-1211(98)00020-5"},{"key":"e_1_3_1_30_2","doi-asserted-by":"crossref","unstructured":"Perucca E Gram L Avanzini G Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39(1): 5\u201317. doi:10.1111\/j.1528-1157.1998.tb01268.x.","DOI":"10.1111\/j.1528-1157.1998.tb01268.x"},{"key":"e_1_3_1_31_2","doi-asserted-by":"crossref","unstructured":"Marson AG Al-Kharusi AM Alwaidh M et al. The SANAD study of effectiveness of carbamazepine gabapentin lamotrigine oxcarbazepine or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369(9566): 1000\u20131015. doi:10.1016\/S0140-6736(07)60460-7.","DOI":"10.1016\/S0140-6736(07)60460-7"},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","unstructured":"Kwan P Brodie MJ Ka\u00a8lvia\u00a8inen R et al. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3 double-blind randomised parallel-group trial. Lancet Neurol 2011; 10(10): 881\u2013890. doi:10.1016\/S1474-4422(11)70154-5.","DOI":"10.1016\/S1474-4422(11)70154-5"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","unstructured":"French J Kwan P Fakhoury T et al. Pregabalin monotherapy in patients with partial-onset seizures: a historical-controlled trial. Neurology 2014; 82(7): 590\u2013597. doi:10.1212\/WNL.0000000000000119.","DOI":"10.1212\/WNL.0000000000000119"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","unstructured":"Hirsch LJ Weintraub D Du Y et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004; 63(6): 1022\u20131026. doi:10.1212\/01.WNL.0000138424.33979.0C.","DOI":"10.1212\/01.WNL.0000138424.33979.0C"},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","unstructured":"Ramey P Osborn M Abou-Khalil B. Conversion from immediate-release to extended-release lamotrigine improves seizure control. Epilepsy Res 2014; 108(9): 1637\u20131641. doi:10.1016\/j.eplepsyres.2014.08.004.","DOI":"10.1016\/j.eplepsyres.2014.08.004"},{"key":"e_1_3_1_36_2","doi-asserted-by":"crossref","unstructured":"Brigo F Ausserer H Tezzon F Nardone R. When one plus one makes three: the quest for rational antiepileptic polytherapy with supraadditive anticonvulsant efficacy. Epilepsy Behav 2013; 27(3): 439\u2013442. doi:10.1016\/j.yebeh.2013.03.010.","DOI":"10.1016\/j.yebeh.2013.03.010"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","unstructured":"Poolos NP Warner LN Humphreys SZ Williams S. Comparative efficacy of combination drug therapy in refractory epilepsy. Neurology 2012; 78(1): 62\u201368. doi:10.1212\/WNL.0b013e31823ed0dd.","DOI":"10.1212\/WNL.0b013e31823ed0dd"},{"key":"e_1_3_1_38_2","doi-asserted-by":"crossref","unstructured":"Pin\u02dca-Garza JE Schwarzman L Wiegand F Hulihan J. A pilot study of topiramate in childhood absence epilepsy. Acta Neurol Scand 2011; 123(1): 54\u201359. doi:10.1111\/j.1600-0404.2010.01347.x.","DOI":"10.1111\/j.1600-0404.2010.01347.x"},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","unstructured":"Hunt S Russell A Smithson WH et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008; 71(4): 272\u2013276. doi:10.1212\/01.wnl.0000318293.28278.33.","DOI":"10.1212\/01.wnl.0000318293.28278.33"},{"key":"e_1_3_1_40_2","doi-asserted-by":"crossref","unstructured":"Azar NJ Bangalore-Vittal N Arain A Abou-Khalil BW. Tiagabine-induced stupor in patients with psychogenic nonepileptic seizures: nonconvulsive status epilepticus or encephalopathy? Epilepsy Behav 2013; 27(2): 330\u2013332. doi:10.1016\/j.yebeh.2013.02.016.","DOI":"10.1016\/j.yebeh.2013.02.016"},{"key":"e_1_3_1_41_2","doi-asserted-by":"crossref","unstructured":"Koepp MJ Edwards M Collins J et al. Status epilepticus and tiagabine therapy revisited. Epilepsia 2005; 46(10): 1625\u20131632. doi:10.1111\/j.1528-1167.2005.00263.x.","DOI":"10.1111\/j.1528-1167.2005.00263.x"},{"key":"e_1_3_1_42_2","doi-asserted-by":"crossref","unstructured":"Fukuyama K Tanahashi S Nakagawa M et al. Levetiracetam inhibits neurotransmitter release associated with CICR. Neurosci Lett 2012; 518(2): 69\u201374. doi:10.1016\/j.neulet.2012.03.056.","DOI":"10.1016\/j.neulet.2012.03.056"},{"key":"e_1_3_1_43_2","doi-asserted-by":"crossref","unstructured":"Sake JK Hebert D Isoja\u00a8rvi J et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010; 24(12): 1055\u20131068. doi:10.2165\/11587550-000000000-00000.","DOI":"10.2165\/11587550-000000000-00000"},{"key":"e_1_3_1_44_2","doi-asserted-by":"crossref","unstructured":"Ben-Menachem E. Medical management of refractory epilepsy\u2014practical treatment with novel antiepileptic drugs. Epilepsia 2014; 55(suppl 1): 3\u20138. doi:10.1111\/epi.12494.","DOI":"10.1111\/epi.12494"},{"key":"e_1_3_1_45_2","doi-asserted-by":"crossref","unstructured":"Ka\u00a8lvia\u00a8inen R Nousiainen I Mantyjarvi M et al. Vigabatrin a gabaergic antiepileptic drug causes concentric visual field defects. Neurology 1999; 53(5): 922\u2013926. doi:10.1212\/WNL.53.5.922.","DOI":"10.1212\/WNL.53.5.922"},{"key":"e_1_3_1_46_2","doi-asserted-by":"crossref","unstructured":"Toggweiler S Wieser HG. Concentric visual field restriction under vigabatrin therapy: extent depends on the duration of drug intake. Seizure 2001; 10(6): 420\u2013423. doi:10.1053\/seiz.2000.0527.","DOI":"10.1016\/S1059-1311(00)90527-2"},{"key":"e_1_3_1_47_2","doi-asserted-by":"crossref","unstructured":"Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia 2015; 56(1): 12\u201327. doi:10.1111\/epi.12865.","DOI":"10.1111\/epi.12865"},{"key":"e_1_3_1_48_2","doi-asserted-by":"crossref","unstructured":"French JA Krauss GL Wechsler RT et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial [published online ahead of print August 21 2015]. Neurology doi:10.1212\/WNL.0000000000001930.","DOI":"10.1212\/WNL.0000000000001930"},{"key":"e_1_3_1_49_2","doi-asserted-by":"crossref","unstructured":"Semah F Thomas P Coulbaut S Derambure P. Early add-on treatment vs alternative monotherapy in patients with partial epilepsy. Epileptic Disord 2014; 16(2): 165\u2013174. doi:10.1684\/epd.2014.0650.","DOI":"10.1684\/epd.2014.0650"},{"key":"e_1_3_1_50_2","doi-asserted-by":"crossref","unstructured":"Zaccara G Perucca E. Interactions between antiepileptic drugs and between antiepileptic drugs and other drugs. Epileptic Disord 2014; 16(4): 409\u2013431. doi:10.1684\/epd.2014.0714.","DOI":"10.1684\/epd.2014.0714"},{"key":"e_1_3_1_51_2","doi-asserted-by":"crossref","unstructured":"Margolis JM Chu BC Wang ZJ et al. Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action. JAMA Neurol 2014; 71(8): 985\u2013993. doi:10.1001\/jamaneurol.2014.808.","DOI":"10.1001\/jamaneurol.2014.808"},{"key":"e_1_3_1_52_2","doi-asserted-by":"crossref","unstructured":"Stafstrom CE. Mechanisms of action of antiepileptic drugs: the search for synergy. Curr Opin Neurol 2010; 23(2): 157\u2013163. doi:10.1097\/WCO.0b013e32833735b5.","DOI":"10.1097\/WCO.0b013e32833735b5"},{"key":"e_1_3_1_53_2","unstructured":"52. US Food and Drug Administration. Information for healthcare professionals: suicidal behavior and ideation and antiepileptic drugs. www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm100192.htm. Updated August 15 2013. Accessed December 13 2015."},{"key":"e_1_3_1_54_2","doi-asserted-by":"crossref","unstructured":"Sirven JI. Management of epilepsy comorbidities. Continuum (Minneap Minn) 2016; 22(1 Epilepsy): 191\u2013203.","DOI":"10.1212\/CON.0000000000000268"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1212\/CON.0000000000000289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:11:16Z","timestamp":1752156676000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/CON.0000000000000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1212\/CON.0000000000000289"],"URL":"https:\/\/doi.org\/10.1212\/con.0000000000000289","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}